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Atrial ﬁbrillation is the most common heart rhythm disorder in the world, with major public health impact
especially due to increased risk of stroke and hospitalizations. The recently published results on epidemiology
of atrial ﬁbrillation from the Global Burden of Diseases, Injuries, and Risk Factors Study conﬁrm the existence
of a signiﬁcant and progressive worldwide increase in the burden of atrial ﬁbrillation. However, there appears
to be regional variation in both the burden of atrial ﬁbrillation and availability of epidemiological data
regarding this condition. In this review, the authors identify issues that are unique to the developed versus
developing regions and outline a road map for possible approaches to surveillance, management, and
prevention of atrial ﬁbrillation at the global level.The authors report no re-
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GLOBAL HEART
© 2014 World HeartAtrial ﬁbrillation (AF) is a common cardiovascular
disorder that contributes signiﬁcantly to risk of symptoms,
hospitalization, and stroke [1]. The recently published
ﬁndings on the worldwide epidemiology of AF from the
GBD 2010 (Global Burden of Diseases, Injuries, and Risk
Factors) study provide clear evidence of a long-suspected
phenomenon—a burgeoning population of patients with
AF on a global level [2]. This study estimated that in 2010,
there were 33.5 million patients with AF in the world,
constituting approximately 0.5% of the total world popu-
lation. Individuals of European descent in high-income
countries appear to have a higher likelihood of devel-
oping AF, resulting in a higher overall burden of AF in
high-income nations. However, there appear to be signiﬁ-
cant differences in the developed versus developing world
related to mortality associated with AF that could have a
signiﬁcant impact on management of AF in these regions
[2]. There are additional considerations in the developing
world that relate to distinct distribution of etiologies, co-
morbid conditions, and approaches to management that are
likely to require unique sets of approaches for these regions
[3,4]. The purpose of this review is to compare AF epide-
miology, burden, and associated mortality in the developed
versus developing nations, with a special focus on the
recently published results of the GBD 2010 study. We have
attempted to identify issues that are unique to these sepa-
rate regions of the world with the overall goal of outlining a
road map for possible approaches to management and
prevention of this condition in what is clearly a sizeable and
growing population of patients with AF at a global level.Federation (Geneva).
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CC BY-NC-ND license.RISING GLOBAL PREVALENCE, INCIDENCE, AND
BURDEN OF AF
AF is the most common heart rhythm disorder worldwide.
Between 1990 and 2010, there was a modest increase inGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 113-119prevalence and a major increase in incidence of AF [2]. In
2010, the prevalence rates per 100,000 population were
596.2 (95% uncertainty intervals [UI]: 558.4 to 636.7) in
men (5% increase since 1990) and 373.1 (95% UI: 347.9
to 402.2) in women (4% increase since 1990). AF inci-
dence per 100,000 population was 77.5 (95% UI: 65.2 to
95.4) in men (28% increase from 1990) and 59.5 (95% UI:
49.9 to 74.9) in women (35% increase from 1990). For
both men and women, prevalence (Fig. 1) and incidence
(Fig. 2) of AF were disproportionately higher in developed
nations compared with developing nations.
In GBD 2010, the burden associated with AF was
measured as disability-adjusted life-years (DALYs). DALYs
combine information regarding premature death (years of
life lost [YLL]) and disability caused by the condition (years
lived with disability [YLD]) [5]. Effects or sequelae of AF
resulting in disability were deﬁned as “daily medication and
at least minimal interference with daily activities.” On the
basis of previously determined disability weights for
sequelae of several disease conditions [6], AF sequelae were
assigned adisabilityweight of 0.031.OneDALY corresponds
to 1 lost year of health and is calculated as YLL þ YLD. In
2010, the estimated age-standardized global burden,
expressed as DALYs, resulting from AF (per 100,000 pop-
ulation) was 64.5 (95% UI: 46.8 to 84.2) in men and 45.9
(95% UI: 35.7 to 58.5) in women, representing increases of
18.8% (95% UI: 15.8 to 19.3) and 18.9% (95% UI: 15.8 to
23.5) for men and women, respectively. Coinciding with the
higher incidence and prevalence of AF in the developed
world, age-standardized DALY rates were higher in devel-
oped compared with developing nations (Fig. 3). An
important consideration while interpreting these new data is
the signiﬁcant lack of community-based data on AF and
other cardiovascular diseases in the developing world and
especially in Sub-Saharan Africa. In fact, this same study
reported that the vast majority of published studies (allj.gheart.2014.01.004
113
FIGURE 1. Age-adjusted prevalence rates of atrial
ﬁbrillation for men and women in developed versus
developing countries (2010). FIGURE 3. Age-adjusted disability-adjusted life year
rates of atrial ﬁbrillation for men and women in devel-
oped versus developing countries (2010).
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114languages) were performed in either Western Europe
(35.9%) or North America (35.6%) [2]. As a result, any
current estimate of the AF global burden is likely to be
affected by this limitation.MORTALITY ASSOCIATED WITH AF
Although overall burden of AF was higher in the developed
nations (inclusive of AF mortality and disability due to
nonfatal AF), the recent GBD 2010 ﬁndings related to
mortality associated with AF in the developed versus
developing nations warrant speciﬁc attention, especially
regarding the difference between sexes [2]. Estimation of
the mortality associated with AF was performed based on
modeling the causes of death after using input from all
available cause of death data. The age-adjusted mortality
rate for AF (per 100,000 population) increased between
1990 and 2010 to 1.6 (95% UI: 1.0 to 2.4) for men and 1.7
(95% UI: 1.4 to 2.2) for women. This represented a 2-fold
(95% UI: 2.0 to 2.2) and 1.9-fold (95% UI: 1.8 to 2.0)FIGURE 2. Age-adjusted incidence rates of atrial ﬁbril-
lation for men and women in developed versus devel-
oping countries (2010).increase for men and women, respectively. Thus, although
AF prevalence rate was substantially lower in women than
in men in both developed and developing countries, global
mortality rate associated with AF was slightly higher in
women; this paradoxical difference appeared to result from
a disproportionately higher mortality rate among women
(1.0) than men (0.7) with AF in the developing than in
developed (2.4 vs. 2.7, respectively) nations (Fig. 4). In the
absence of systematic studies that could explain the higher
mortality among women in developing nations, there are a
few potential explanations. This ﬁnding could be explained
in part by the types of AF-associated conditions that are
signiﬁcantly more prevalent among women in the devel-
oping world compared with the developed world. One
important example could be AF related to valve disease.
The vast majority of patients with AF in developed nations
have nonvalvular AF. In the developing world, a signiﬁcant
proportion is likely to have valvular AF, most likely related
to rheumatic heart disease [7]. Because rheumatic heart
disease may be more common among women [8], with a
signiﬁcant proportion manifesting during pregnancy [9],
this factor needs to be explored as a potential explanation
for the higher mortality rates observed among women with
AF in developing nations. Another factor could be the
lower social status and poorer access to medical care of
women than men in many developing countries. Finally,
misclassiﬁcation bias in death records will need to be
evaluated, with the reported underlying cause being
attributed more commonly to AF for women than for men.
SEX DIFFERENCES IN AF AT A GLOBAL LEVEL
Sex differences in the death rate due to AF vary across
regions of the world, even within the developed and
developing categories. The highest disparity is seen in East
Asia, where age-adjusted mortality due to AF in 2010 wasGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 113-119
FIGURE 4. Mortality associated with AF stratiﬁed by sex and type of region (developed vs. developing). Mortality
associated with atrial ﬁbrillation (AF) was higher in males and females in developed regions. However, the dispro-
portionately higher mortality in females in developing regions was responsible for the overall higher AF-related mor-
tality among females compared with males. ªAmerican Heart Association (Reprinted from: Chugh SS, Havmoeller R,
Narayanan K, et al. Worldwide epidemiology of atrial ﬁbrillation: a Global Burden of Disease 2010 study. Circulation
2014;129:837-47 [2]).
gREVIEWjmore than twice as high in women (1.32 deaths per
100,000; 95% uncertainty interval [UI]: 0.49 to 2.92)
compared with men (0.58; 95% UI: 0.17 to 1.6). This
female predominance in AF-related deaths also occurred in
Central, Western, and Eastern Sub-Saharan Africa and
South Asia. In contrast, some regions had markedly higherTABLE 1. Regional distribution of atrial ﬁbrillation-associated mortal
Location Sex
Deaths
per 100,000 Upper
East Asia Female 1.32 2.92
Central Sub-Saharan Africa Female 0.64 1.37
Western Sub-Saharan Africa Female 0.72 1.65
Eastern Sub-Saharan Africa Female 0.57 1.16
South Asia Female 0.75 1.86
Andean Latin America Female 0.75 1.02
Western Europe Female 3.69 4.57
Southeast Asia Female 0.30 0.41
High-income North America Female 2.57 4.71
Australasia Female 2.96 5.48
Eastern Europe Female 0.38 0.65
Central Latin America Female 0.79 1.07
Latin America and Caribbean Female 1.20 1.61
Southern Latin America Female 1.54 2.23
Southern Sub-Saharan Africa Female 1.63 2.52
Oceania Female 2.96 6.08
North Africa and Middle East Female 1.28 1.69
Central Europe Female 1.16 1.42
High-income Asia Paciﬁc Female 1.45 2.40
Central Asia Female 0.11 0.15
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March 2014: 113-119death rates in men than in women. For example, the high-
income countries of the Asia Paciﬁc region had age-adjusted
mortality rates due to AF of 2.44 deaths per 100,000 (95%
UI: 1.27 to 4.50) among men but only 1.45 (95% UI: 0.86
to 2.40) among women. These sex differences between men
and women are not seen in high-income North America,ity rates in males and females
Lower Sex
Deaths
per 100,000 Upper Lower
Ratio of Male
to Female
Death Rates
0.49 Male 0.58 1.60 0.17 2.26
0.26 Male 0.31 1.02 0.09 2.05
0.28 Male 0.37 1.04 0.12 1.94
0.24 Male 0.34 0.96 0.11 1.67
0.23 Male 0.54 1.95 0.09 1.39
0.53 Male 0.64 0.97 0.39 1.18
2.97 Male 3.42 4.83 2.21 1.08
0.22 Male 0.28 0.43 0.19 1.04
1.38 Male 2.84 5.69 1.49 0.90
1.59 Male 3.39 5.93 1.81 0.87
0.19 Male 0.44 0.73 0.23 0.86
0.59 Male 0.91 1.36 0.62 0.86
0.93 Male 1.40 2.24 0.96 0.86
1.07 Male 2.00 2.92 1.35 0.77
1.07 Male 2.12 4.04 1.08 0.77
1.24 Male 3.88 7.49 1.37 0.76
0.96 Male 1.71 2.84 1.03 0.75
0.95 Male 1.63 2.24 1.06 0.71
0.86 Male 2.44 4.50 1.27 0.60
0.08 Male 0.29 0.42 0.20 0.37
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FIGURE 5. Average age at time of death associated with
atrial ﬁbrillation in high- versus low-income regions.
AFib, atrial ﬁbrillation.
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The cause of these sex disparities is unclear and deserves
further investigation to determine whether it reﬂects differ-
ences in risk factors, health system performance, or even
biases in the attribution of deaths in vital registration. Sex
disparities in age at time of death are also observed globally.
The age at death associated with AF in 2010 was older in
women than in men across all regions of the world. The
differences were greatest in the low- and middle-income
regions of Eastern Europe/Central Asia, East Asia/Paciﬁc,
and Sub-Saharan Africa. However, the age of death associ-
ated with AF increased across all regions between 1990 and
2010 (Fig. 5).
FACTORS CONTRIBUTING TO RISE IN GLOBAL AF
BURDEN
Although AF is a complex and multifactorial condition,
there are several risk factors that have been identiﬁed, most
of which can be readily assessed for individual patients in
primary care settings. In a recent report, a simple 5-year
predictive model that included the variables age, race,
height, weight, systolic and diastolic blood pressure, cur-
rent smoking, use of antihypertensive medication, diabetes,
and history of myocardial infarction and heart failure had
acceptable discrimination (C-statistic: 0.765; 95% CI:
0.748 to 0.781) [10]. Are there trends in AF risk factors at a
global level that could explain the rising burden of AF? It
may be instructive to evaluate key AF risk factors in the
context of the understanding of current global healthtrends, especially as reported by the recently completed
GBD 2010 project.
Aging trends of the world population
Population aging is a well-studied phenomenon and a
powerful determinant of the total global burden of diseases
of aging such as AF [11]. The number of people aged 60 and
older doubled between 1980 and 2012 [12]. By 2050, 2
billion people (22% of the total) are projected to be 60 years
and older, with the most rapid changes occurring in coun-
tries like Brazil and China. The percentage of the population
65 years and older increased from 6.2% in 1990 to 6.9% in
2000 to 7.7% in 2010 and is expected to reach 16.1% by
2050 [13]. It took 69 years for the percentage to double from
7% to 14% in the United States (1944 to 2013), but this
doubling of the over 65 age group is expected to occur in
only 26 years in China (2000 to 2026). The burden of AF at
age 65 years (226 DALYs/100,000) is nearly 7 times that at
age 45 years (33 DALYs/100,000) and only one-quarter that
at ages 80 and older (936DALYs/100,000). Population aging
will be associated with rapidly increasing numbers of per-
sons living with chronic conditions such as AF, ischemic
heart disease, and stroke and increasing healthcare costs.
Hypertension and cardiovascular disease
Hypertension is a powerful independent risk factor for
cardiovascular disease and the leading risk factor for dis-
ease burden worldwide [3]. Like AF, it is also very com-
mon, affecting nearly 1 in 3 adults worldwide. More than a
billion people had hypertension in 2008, with an estimated
978 million individuals who had uncontrolled high blood
pressure (systolic blood pressure 140 mm Hg or diastolic
blood pressure 90 mm Hg) [14]. Given these numbers, it
would not be uncommon to ﬁnd the coexistence of hy-
pertension and AF. However, there are hemodynamic and
pathophysiological bases for an association of hypertension
and AF. Chronic exposure of the cardiovascular system to
hypertension leads to left ventricular pressure overload,
resulting in increased left atrial pressure, left atrial
enlargement, and left atrial hypertrophy [15]. Besides hy-
pertension, other cardiovascular diseases in which left atrial
pressure or volume overload occurs (as in mitral stenosis
or regurgitation, left ventricular diastolic heart failure,
and severe systolic heart failure with cardiac chamber
enlargement) also predispose to AF. In addition, chronic
hypertension and heart failure lead to activation of the
renin-angiotensin-aldosterone (RAA) axis, with resultant
myocardial and atrial ﬁbrosis predisposing to AF. Not
surprisingly, recent studies have shown that therapeutic
antagonism or blockade of the RAA axis can be effective for
both primary and secondary prevention of AF in patients
with hypertension [15]. More recently, a molecular genetic
basis of AF has been suggested [16]. Several genetic asso-
ciation studies have shown that genetic variants or poly-
morphisms linked to AF are also associated with genes
related to ionic channels, calcium handling proteins,GLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 113-119
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ﬁbrosis, conduction, and inﬂammatory processes impor-
tant in the pathogenesis of common AF as well as several
cardiovascular diseases [16,17].
Obesity and the metabolic syndrome
Obesity and the metabolic syndrome have been linked to
increased risk of AF. In the prospective Framingham
Heart study, obesity was associated with a 4% to 5%
increased risk of AF over a mean follow-up of 14 years,
independently of hypertension, diabetes, and myocardial
infarction [18]. The same study reported that this rela-
tionship may be mediated by an increase in left atrial
diameter, a risk factor that can be at least partially
attenuated by weight loss [19]. However, it is likely that
AF in obesity is determined by multiple factors that
include overlap with the metabolic syndrome [20], as well
as obstructive sleep apnea [21,22]. The Women’s Health
study reported a linear relationship between body mass
index (BMI) and AF, with a 5% increase in risk of AF for
a 1-unit increase in BMI [23].
Diabetes
Several studies have reported a modestly increased inci-
dence or prevalence of AF among patients with type 2
diabetes [24] and an increased incidence of stroke among
patients with diabetes with AF [25]. However, other
studies have failed to ﬁnd a signiﬁcant association. If future
studies conﬁrm diabetes as a risk factor for AF, the obesity-
related risk in occurrence of type 2 diabetes must be
considered as a contributor to the rising occurrence of AF.
FACTORS RELATED TO RACE AND ETHNICITY THAT
INCREASE RISK OF AF
White European descent
There are strong indications that individuals of white
European descent have a higher risk of AF compared with
individuals of other races, a ﬁnding that at least partially
explains the signiﬁcantly higher prevalence of AF in
developed nations. In a cross-sectional study of 1.89
million adults aged 20 years or older enrolled in a large
health maintenance organization in California, AF was
identiﬁed in 1% [26]. In this large, ethnically diverse
population, AF was more common in white (2.2%) than in
black (1.5%; p < 0.001) patients. Similar results were
recently reported from a comparison between white and
black older adults [27], also conﬁrmed using genetic
testing for ancestry informative markers [28]; however,
there is a lack of data for other races. Consistent with these
ﬁndings, European Union estimates indicated that 8.8
million adults older than 55 years had AF in 2010 (95%
CI: 6.5 to 12.3 million), comprising >25% of the world-
wide AF population [29]. These numbers are projected to
double by 2060 to 17.9 million (95% CI: 13.6 to 23.7
million), as long as age- and sex-speciﬁc prevalence re-
mains stable [29].GLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 113-119Body height and AF
In the few analyses that have been conducted, a consistent
relationship has been identiﬁed between body height and
risk of AF, which may partly explain the higher AF prev-
alence in high-income countries. Among 684 male and 568
female incident cases of AF in the Cardiovascular Health
study, greater height was signiﬁcantly associated with risk
of AF, with hazard ratios per 10 cm of 1.26 and 1.32 for
men and women, respectively [30]. In fact, the incremental
risk of AF from male sex was completely attenuated by the
inclusion of height. In this detailed study, echocardio-
graphic left atrial size, commonly believed to be the
mediator of this relationship, did not explain the associa-
tion between greater height and AF, with the intriguing
possibility that genetic mechanisms may play a role [30].
Two of the genetic loci associated with AF, paired-like
homeodomain 2 [31] and zinc ﬁnger homeobox 3 [32],
are also associated with growth pathways. The lower rates
of AF in some regions of the developing world, especially
South Asia, could in part be explained by the established
differences in height from individuals of white European
descent in the developed world [33]. In addition, both
height and left atrial size are smaller in women compared
with men and may explain in part the signiﬁcantly higher
prevalence of AF in men [34].IMPLICATIONS
Investment in regional AF surveillance
High-quality epidemiological studies at the local, national,
and regional levels will be essential if we are to estimate the
regional and global burden of AF with accuracy. At pre-
sent, systematic population-based surveillance of AF is
scarce, especially in low- and middle-income countries.
Where surveys have been conducted, there is marked
heterogeneity in diagnostic methods, clinical settings, and
the presence or absence of symptoms [35]. In light of
recent ﬁndings in population growth and aging, and the
associated epidemiological transition with increasing
burden of chronic noncommunicable diseases that pre-
dispose to AF, a strong case can be made for increased
investment in AF surveillance. The 2 approaches that have
been proposed to increase the rate of detection of incident
cases to enable early intervention, especially for the pre-
vention of stroke and other sequelae of AF, are 1) sys-
tematic and 2) opportunistic screening for AF [36]. In a
review of evidence from the United Kingdom, Moran et al.
[36] recently showed that although both approaches
compared favorably on AF diagnosis rate, from the health
service provider perspective, the cost of systematic
screening was signiﬁcantly more than that of opportunistic
screening. There are speciﬁc challenges involved in AF
surveillance because the condition can often be asymp-
tomatic as well as sporadic (or paroxysmal). This will
require the development of innovative approaches likely
involving current mobile and wireless technologies.117
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Interventions to prevent or delay AF and other cardiovas-
cular conditions offer the best hope for moderating the
future burden of these diseases. Evidence is lacking to
recommend speciﬁc interventions for the prevention of AF
beyond those generally recommended for hypertension
control and prevention of ischemic heart disease and
stroke. However, clinical and epidemiological evidence
suggests that diagnosis, close supervision, and manage-
ment of patients with obstructive sleep apnea, likely
feasible only in high-income countries, may be of value in
preventing AF. Further, avoidance of heavy alcohol intake
(i.e., greater than 2 drinks daily in men or 1 drink daily in
women) may also be prudent.
Approach to stroke prophylaxis
In the developing world, there is a distinct lack of studies
that have assessed prevalence of stroke prophylaxis. Given
the economic challenges of establishing an infrastructure of
warfarin clinics that would monitor the international
normalized ratio, the majority of patients in low-resource
settings likely receive aspirin as antithrombotic therapy.
The low use of oral anticoagulants (in the range of 0.5%
to 3%) [7,37] in low-income countries is in stark contrast to
the signiﬁcantly higher use in high-income countries (in the
range of 70%) [38]. However, even in high-income coun-
tries, prevalence of oral anticoagulation is lower than ex-
pected, with fewer than two-thirds of high-risk patients on
oral anticoagulation [39], likely due to concerns regarding
bleeding risk in an aging population and the challenges of
achieving adequate and safe adherence. Along with signiﬁ-
cant variability in regional burden of AF, attitudes toward
and practice of stroke prophylaxis are likely to be heteroge-
neous. The major efforts conducted in high-income countries
to establish guidelines for stroke prophylaxis and bleeding
risk have not even been initiated in low-income countries.
Systematic surveillance of stroke prophylaxis patterns and
assessment of potential beneﬁcial and harmful effects attrib-
utable to oral anticoagulation versus aspirin therapy in
developing nations will provide the region-speciﬁc basis for
the establishment of guidelines that would educate health-
care providers as well as the population.
Management of symptoms and hospitalizations
due to AF
The large randomized trials of AF management conducted
primarily in high-income nations provide strong evidence
for the equivalence of rate versus rhythm control in the older
patient with at least moderate risk of stroke, as long as
anticoagulation guidelines are followed. However, there exist
large numbers of patients at all ages who require ameliora-
tion of symptoms due to AF by use of rhythm control.
Antiarrhythmic drugs have long been the main therapeutic
approach with pacemaker implantationeatrioventricular
junction ablation and the surgical maze procedure used for a
selected subgroup of patients. Almost 2 decades ago,therapeutic catheter-based radiofrequency ablation was
introduced into the AF treatment armamentarium and is
currently ﬁnding increasing use but is restricted largely to
high-income countries [40]. Although comparative evalua-
tion of these different treatment modalities is ongoing [41],
the growing burden of AF will also require assessment at a
population level. Is it possible that the one-time expense of
an electrophysiological procedure is more cost effective than
long-term rate control and anticoagulation in low-resource
settings, with limited chronic care infrastructure in some
cases? The answer to this question is likely to be complex
given both the regional heterogeneity in AF burden as well
as disparities in allocation of resources in developed versus
developing countries. It is therefore imperative that regional
AF surveillance be combined with comparative effectiveness
evaluation of different AF management approaches.
SUMMARY
New ﬁndings from the GBD 2010 study indicated that the
last 2 decades have witnessed a signiﬁcant rise in the
worldwide prevalence, incidence, and overall burden of AF.
Although the burden of AF is greater in high-income
countries (possibly due to increased predilection for AF
among white Europeans), mortality associated with AF in
women is higher in low-income countries. This latter ﬁnding
is currently unexplained and warrants urgent attention. Be-
sides the older age of the global population, other factors
such as the rising tide of hypertension, obesity, and diabetes
could contribute to the overall increased global burden of
AF. Given the signiﬁcant variation in AF burden in both
developing and developed nations, there is a critical need for
investment in regional AF surveillance that will serve as a
starting point for region-based prevention of AF, stroke
prophylaxis, and systematic approaches to manage symp-
toms and hospitalizations due to AF.REFERENCES
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